Impact of P53 and SIRT1 in Type 2 Diabetes

DM Clinical Trial

Official title:
Investigating the Impact of p53 and SIRT1 in the Development of Type 2 DM Through the Treatment of Prediabetic Individuals by Either Nigetella Salivata or Metformin

Status Recruiting

Clinical Trial Summary

Investigating the impact of p53 and SIRT1 in the development of type 2 DM

Clinical Trial Description

Investigating the impact of p53 and SIRT1 in the development of type 2 DM through the treatment of prediabetic individuals by either nigetella salivata or Metformin ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT03925714
Study type	Interventional
Source	Tanta University
Contact	Sherief Abd-Elsalam, ass. prof.
Phone	00201147773440
Email	sheriefabdelsalam@yahoo.com
Status	Recruiting
Phase	Phase 3
Start date	April 1, 2019
Completion date	December 2028

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT01094418` - Electrodiagnostic Parameters in Patients With Impaired Glucose Tolerance and Diabetes Mellitus	N/A
Completed	`NCT00587301` - Lap-Band Surgery on Adolescents for Safety and Efficacy	N/A
Recruiting	`NCT01830998` - Early Detection of Cognitive Dysfunction in Diabetes	N/A
Recruiting	`NCT05372458` - The Mechanism Study of Diabetic Pancreatic Amyloid Deposition on Cognitive Dysfunction in Alzheimer's Disease
Recruiting	`NCT03925701` - Clinical Study Evaluating Vildagliptin Versus Vildagliptin/Metformin on NAFLD With DM	Phase 3